/BMY
BMY Stock - Bristol-Myers Squibb Company
Healthcare|Drug Manufacturers - GeneralNYSE
$54.19+1.61%
+$0.86 (+1.61%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).49
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-0.4%upside
Target: $53.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BMY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$53.65 – $54.73
TARGET (TP)$54.00
STOP LOSS$49.85
RISK/REWARD1:-0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$63.33
52W Low$42.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B |
| Gross Profit | $27.43B | $25.36B | $26.49B | $26.76B | $21.70B |
| Gross Margin | 56.8% | 56.3% | 57.4% | 57.7% | 51.0% |
| Operating Income | $9.66B | $8.47B | $9.27B | $9.54B | $4.49B |
| Net Income | $-8,948,000,000 | $8.03B | $6.33B | $6.99B | $-8,995,000,000 |
| Net Margin | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% |
| EPS | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.98 |
Company Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
26%
Hold / Neutral
17
74%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
6 Bullish17 Neutral/Bearish
Price Targets
$61
Average Target
↑ 11.9% Upside
Now
$41
Low
$61
Average
$95
High
Based on 26 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | BofA Securities | Upgrade | Buy | $61 |
| December 12th 2025 | Guggenheim | Upgrade | Buy | $62 |
| November 13th 2025 | Scotiabank | Initiation | Sector Perform | $45 |
| August 5th 2025 | Daiwa Securities | Downgrade | Neutral | $42 |
| April 22nd 2025 | Cantor Fitzgerald | Initiation | Neutral | $55 |
| April 22nd 2025 | Piper Sandler | Initiation | Overweight | - |
| December 16th 2024 | Jefferies | Upgrade | Buy | $70 |
| December 10th 2024 | BofA Securities | Resumed | Neutral | $63 |
| November 15th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| November 13th 2024 | Daiwa Securities | Upgrade | Outperform | - |
| November 12th 2024 | Leerink Partners | Upgrade | Outperform | $73 |
| October 25th 2024 | Citigroup | Downgrade | Neutral | $55← $75 |
| October 17th 2024 | Bernstein | Initiation | Market Perform | $56 |
| July 29th 2024 | Barclays | Downgrade | Equal Weight | $41 |
| March 11th 2024 | Societe Generale | Downgrade | Hold | - |
Earnings History & Surprises
BMYBeat Rate
88%
Last 16 quarters
Avg Surprise
+10.4%
EPS vs Estimate
Beats / Misses
14/1
1 met exactly
Latest EPS
$1.63
Q4 2025
EPS Surprise History
Q1 24
+11.8%
$1.70vs$1.52
Q2 24
+0.2%
$-4.40vs$-4.41
Q3 24
+27.8%
$2.07vs$1.62
Q4 24
+20.8%
$1.80vs$1.49
Q1 25
+13.6%
$1.67vs$1.47
Q2 25
+20.8%
$1.80vs$1.49
Q3 25
+33.9%
$1.46vs$1.09
Q4 25
+7.2%
$1.63vs$1.52
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2026 | Oct 29, 2026 | — | — | — | — |
Q3 2026 | Jul 30, 2026 | — | — | — | — |
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $1.71 | — | — | — |
Q4 2025 | Oct 30, 2025 | $1.52 | $1.63 | +7.2% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $1.09 | $1.46 | +33.9% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $1.49 | $1.80 | +20.8% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $1.47 | $1.67 | +13.6% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $1.49 | $1.80 | +20.8% | ✓ BEAT |
Q3 2024 | Jul 26, 2024 | $1.62 | $2.07 | +27.8% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $-4.41 | $-4.40 | +0.2% | ✓ BEAT |
Q1 2024 | Feb 2, 2024 | $1.52 | $1.70 | +11.8% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $1.76 | $2.00 | +13.6% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $1.99 | $1.75 | -12.1% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $1.98 | $2.05 | +3.5% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $1.71 | $1.82 | +6.4% | ✓ BEAT |
Q4 2022 | Oct 25, 2022 | $1.83 | $1.99 | +8.7% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $1.79 | $1.93 | +7.8% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $1.92 | $1.96 | +2.1% | ✓ BEAT |
Q1 2022 | Feb 4, 2022 | $1.83 | $1.83 | 0.0% | = MET |
Latest News
Shars of drug companies are higher after announcing deals with President Trump for lower drug prices.
📈 PositiveBenzinga•Dec 19, 2025, 08:34 PM•Also: , ,
Bristol Myers Squibb To Provide Eliquis Free To Medicaid Program, Donate Over Seven Tons Of API For U.S. Supply; Receives 3-Years Of Tariff Relief
📈 PositiveBenzinga•Dec 19, 2025, 08:07 PM
Bristol Myers Squibb Most-Favored-Nation Pricing To American Patients Will Contribute Tablets Representing 6.5 Tons Of Apixaban, The Active Ingredient In The Drug Eliquis, A Blood Thinner Taken By Millions Of American Patients
📈 PositiveBenzinga•Dec 19, 2025, 07:58 PM
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Senior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveBenzinga•Dec 19, 2025, 07:20 PM•Also: , ,
'Several top drugmakers to lower US prices for some drugs-sources' - Reuters
📈 PositiveBenzinga•Dec 19, 2025, 12:42 PM•Also: , ,
Bristol-Myers Squibb shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $52 to $61.
📈 PositiveBenzinga•Dec 15, 2025, 01:52 PM
B of A Securities Upgrades Bristol-Myers Squibb to Buy, Raises Price Target to $61
📈 PositiveBenzinga•Dec 15, 2025, 11:45 AM
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $37
➖ NeutralBenzinga•Dec 12, 2025, 05:22 PM
Guggenheim Upgrades Bristol-Myers Squibb to Buy, Announces $62 Price Target
📈 PositiveBenzinga•Dec 12, 2025, 01:46 PM
Bristol Myers Squibb Gets FDA Priority Review for Opdivo Plus AVD Combination sBLA In Untreated Stage III/IV cHL; PDUFA April 8, 2026
📈 PositiveBenzinga•Dec 11, 2025, 12:01 PM
Bristol Myers Squibb Raises Dividend From $0.62 To $0.63/Share
📈 PositiveBenzinga•Dec 10, 2025, 09:28 PM
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $55
➖ NeutralBenzinga•Dec 10, 2025, 08:09 PM
BioNTech And Bristol Myers Report Early Data For New Triple-Negative Breast Cancer Treatment
📈 PositiveBenzinga•Dec 9, 2025, 12:07 PM•Also:
Bristol Myers Squibb Highlights New Research Across Multiple Therapies For Patients With Lymphoma At ASH Annual Meeting.
📈 PositiveBenzinga•Dec 8, 2025, 09:36 PM
FDA Approves First CAR T-Cell Therapy For Marginal Zone Lymphoma In The US; Approved A New Indication For Breyanzi
📈 PositiveBenzinga•Dec 4, 2025, 10:07 PM
Scotiabank Maintains Sector Perform on Bristol-Myers Squibb, Raises Price Target to $53
➖ NeutralBenzinga•Dec 4, 2025, 08:00 PM
Bristol-Myers Squibb shares are trading higher after the company announced that it will enroll additional patients in the ADEPT-2 study.
📈 PositiveBenzinga•Dec 3, 2025, 01:32 PM
Bristol Myers Squibb To Enroll Additional Patients In ADEPT-2 Study
➖ NeutralBenzinga•Dec 3, 2025, 12:00 PM
Goldman Sachs Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $57
➖ NeutralBenzinga•Dec 2, 2025, 06:13 PM
Frequently Asked Questions about BMY
What is BMY's current stock price?
Bristol-Myers Squibb Company (BMY) is currently trading at $54.19 per share. The stock has moved +1.61% today.
What is the analyst price target for BMY?
The average analyst price target for BMY is $54.00, based on 1 analyst.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is BMY's market cap?
Bristol-Myers Squibb Company has a market capitalization of $110.32 billion, making it a large-cap company.
Does BMY pay dividends?
No, Bristol-Myers Squibb Company does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCI
Cigna Corporation
$271.89
Mkt Cap: $72.6B
CVS
CVS Health Corporation
$77.72
Mkt Cap: $98.7B
ELV
Elevance Health Inc.
$340.69
Mkt Cap: $75.7B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
HCA
HCA Healthcare, Inc.
$472.98
Mkt Cap: $114.8B
MCK
McKesson Corporation
$820.25
Mkt Cap: $102.5B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
VRTX
Vertex Pharmaceuticals Incorporated
$456.20
Mkt Cap: $117.1B
ZTS
Zoetis Inc.
$122.24
Mkt Cap: $53.9B
Explore stocks similar to BMY for comparison